Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Information on the prognostic value of immunoparesis (IP) recovery in multiple myeloma (MM) patients has been only generated in some observational and retrospective studies. We have evaluated the prognostic impact of IP recovery and its association with minimal residual disease (MRD) in a series of...

Descripción completa

Detalles Bibliográficos
Autores: Lakhwani, S, Mateos, MV, Martinez-López, J, Paiva, B, Dachs, LR, Martínez, R, Oriol, A, Bargay, J, González-Montes, Y, Gironella, M, Encinas, C, Martín, J, Jarque, I, Granell, M, Abella, E, García-Mateo, A, Hernández-Rivas, JA, Ramila, E, Krsnik, I, Montero, LFC, De Arriba, F, Palomera, L, Sampol, A, Moraleda, JM, Casanova, M, Delgado, P, Lafuente, A, Amutio, E, López-Martínez, A, Altés, A, Ruíz, MA, Alegre, A, Lopez-Anglada, L, de la Cruz, J, Fernández, RA, Creixenti, JB, Lahuerta, JJ, San-Miguel, J, Hernández, MT
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p5315
Acceso en línea:https://i3pt.portalinvestigacion.com/publicaciones/5315
Access Level:acceso abierto
Palabra clave:Immunoparesis
Myeloma
Minimal residual disease
Immunoglobulin
id ES_fce11332fa83a12f576e3665d5ddfc5e
oai_identifier_str oai:i3pt.fundanetsuite.com:p5315
network_acronym_str ES
network_name_str España
repository_id_str
spelling Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual diseaseLakhwani, SMateos, MVMartinez-López, JPaiva, BDachs, LRMartínez, ROriol, ABargay, JGonzález-Montes, YGironella, MEncinas, CMartín, JJarque, IGranell, MAbella, EGarcía-Mateo, AHernández-Rivas, JARamila, EKrsnik, IMontero, LFCDe Arriba, FPalomera, LSampol, AMoraleda, JMCasanova, MDelgado, PLafuente, AAmutio, ELópez-Martínez, AAltés, ARuíz, MAAlegre, ALopez-Anglada, Lde la Cruz, JFernández, RACreixenti, JBLahuerta, JJSan-Miguel, JHernández, MTImmunoparesisMyelomaMinimal residual diseaseImmunoglobulinInformation on the prognostic value of immunoparesis (IP) recovery in multiple myeloma (MM) patients has been only generated in some observational and retrospective studies. We have evaluated the prognostic impact of IP recovery and its association with minimal residual disease (MRD) in a series of 113 newly diagnosed transplant-ineligible (NDTI) patients, that received fix duration treatment (18 cycles of VMP/lenalidomide-dexamethasone) within the PETHEMA/GEM2010MAS65 trial and who achieved CR or VGPR. Immunoglobulin levels were measured at diagnosis, at the end of treatment (after cycle 18th) and during subsequent follow up whereas MRD was analyzed only at the end of the treatment (after cycle 18th). We found that patients who had IP at diagnosis and recovered it during or after treatment had longer progression free survival (PFS) [p < 0.001; HR 0.32 (0.19-0.52)] and longer overall survival (OS) [p = 0.007; HR 0.40 (0.20-0.80)] compared to those who failed to recover it. When we analyzed IP recovery in MRD negative patients, we found that those cases with IP recovery had longer PFS [p = 0.007; HR 0.31 (0.13-0.76)] and longer OS [p = 0.012; HR 0.21 (0.06-0.80)] as compared to MRD negative patients but without IP recovery. In conclusion, IP recovery confers better prognosis in NDTI-MM patients with fixed duration treatment who achieve CR or VGPR and the prognostic value of MRD can be complemented when combined with IP recovery.SPRINGER2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/5315ANNALS OF HEMATOLOGYISSN: 09395555ISSNe: 14320584reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p53152026-06-21T15:30:37Z
dc.title.none.fl_str_mv Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
title Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
spellingShingle Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
Lakhwani, S
Immunoparesis
Myeloma
Minimal residual disease
Immunoglobulin
title_short Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
title_full Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
title_fullStr Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
title_full_unstemmed Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
title_sort Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
dc.creator.none.fl_str_mv Lakhwani, S
Mateos, MV
Martinez-López, J
Paiva, B
Dachs, LR
Martínez, R
Oriol, A
Bargay, J
González-Montes, Y
Gironella, M
Encinas, C
Martín, J
Jarque, I
Granell, M
Abella, E
García-Mateo, A
Hernández-Rivas, JA
Ramila, E
Krsnik, I
Montero, LFC
De Arriba, F
Palomera, L
Sampol, A
Moraleda, JM
Casanova, M
Delgado, P
Lafuente, A
Amutio, E
López-Martínez, A
Altés, A
Ruíz, MA
Alegre, A
Lopez-Anglada, L
de la Cruz, J
Fernández, RA
Creixenti, JB
Lahuerta, JJ
San-Miguel, J
Hernández, MT
author Lakhwani, S
author_facet Lakhwani, S
Mateos, MV
Martinez-López, J
Paiva, B
Dachs, LR
Martínez, R
Oriol, A
Bargay, J
González-Montes, Y
Gironella, M
Encinas, C
Martín, J
Jarque, I
Granell, M
Abella, E
García-Mateo, A
Hernández-Rivas, JA
Ramila, E
Krsnik, I
Montero, LFC
De Arriba, F
Palomera, L
Sampol, A
Moraleda, JM
Casanova, M
Delgado, P
Lafuente, A
Amutio, E
López-Martínez, A
Altés, A
Ruíz, MA
Alegre, A
Lopez-Anglada, L
de la Cruz, J
Fernández, RA
Creixenti, JB
Lahuerta, JJ
San-Miguel, J
Hernández, MT
author_role author
author2 Mateos, MV
Martinez-López, J
Paiva, B
Dachs, LR
Martínez, R
Oriol, A
Bargay, J
González-Montes, Y
Gironella, M
Encinas, C
Martín, J
Jarque, I
Granell, M
Abella, E
García-Mateo, A
Hernández-Rivas, JA
Ramila, E
Krsnik, I
Montero, LFC
De Arriba, F
Palomera, L
Sampol, A
Moraleda, JM
Casanova, M
Delgado, P
Lafuente, A
Amutio, E
López-Martínez, A
Altés, A
Ruíz, MA
Alegre, A
Lopez-Anglada, L
de la Cruz, J
Fernández, RA
Creixenti, JB
Lahuerta, JJ
San-Miguel, J
Hernández, MT
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Immunoparesis
Myeloma
Minimal residual disease
Immunoglobulin
topic Immunoparesis
Myeloma
Minimal residual disease
Immunoglobulin
description Information on the prognostic value of immunoparesis (IP) recovery in multiple myeloma (MM) patients has been only generated in some observational and retrospective studies. We have evaluated the prognostic impact of IP recovery and its association with minimal residual disease (MRD) in a series of 113 newly diagnosed transplant-ineligible (NDTI) patients, that received fix duration treatment (18 cycles of VMP/lenalidomide-dexamethasone) within the PETHEMA/GEM2010MAS65 trial and who achieved CR or VGPR. Immunoglobulin levels were measured at diagnosis, at the end of treatment (after cycle 18th) and during subsequent follow up whereas MRD was analyzed only at the end of the treatment (after cycle 18th). We found that patients who had IP at diagnosis and recovered it during or after treatment had longer progression free survival (PFS) [p < 0.001; HR 0.32 (0.19-0.52)] and longer overall survival (OS) [p = 0.007; HR 0.40 (0.20-0.80)] compared to those who failed to recover it. When we analyzed IP recovery in MRD negative patients, we found that those cases with IP recovery had longer PFS [p = 0.007; HR 0.31 (0.13-0.76)] and longer OS [p = 0.012; HR 0.21 (0.06-0.80)] as compared to MRD negative patients but without IP recovery. In conclusion, IP recovery confers better prognosis in NDTI-MM patients with fixed duration treatment who achieve CR or VGPR and the prognostic value of MRD can be complemented when combined with IP recovery.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/5315
url https://i3pt.portalinvestigacion.com/publicaciones/5315
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER
publisher.none.fl_str_mv SPRINGER
dc.source.none.fl_str_mv ANNALS OF HEMATOLOGY
ISSN: 09395555
ISSNe: 14320584
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425489755504640
score 15,812429

Similares en LA Referencia